Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARISMA trial of colchicine for high-risk non-obstructive coronary artery disease
ACTRN12621000665831Phase 2Recruiting
- Sponsor
- Monash Cardiovascular Research Centre
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing Standard therapy plus colchicine with Standard therapy plus placebo (2 arms). Primary endpoint: Percentage change in peri-coronary adipose tissue attenuation. Started Jul 2022; status: recruiting.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12621000665831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000665831.